Transitioning to Value Based Medical Care Payments

Five Best Practices for Health Plans

http://www.MCOL.com

***

***

Conclusion

Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, urls and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com

OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:

Risk Management, Liability Insurance, and Asset Protection Strategies for Doctors and Advisors: Best Practices from Leading Consultants and Certified Medical Planners™8Comprehensive Financial Planning Strategies for Doctors and Advisors: Best Practices from Leading Consultants and Certified Medical Planners™

***

Advertisements

One Response

  1. Value Based Rx Contracting Tactics and Techniques: Navigating Legal and Regulatory Complexities

    Value-based pharmaceutical contracts, sometimes referred to as risk sharing agreements between pharmaceutical manufacturers and health plans or other purchasers are critical in today’s very complex and costly healthcare marketplace. These agreements allow placement of high-risk, high-cost and often times specialty pharmaceutical products onto purchaser formularies through basing payment on outcomes as opposed to volume metrics. The concept has become popular in single payor systems, and is beginning to take flight in the U.S. as evidenced by several high profile value based contracts between pharmaceutical manufacturers and health plans. However, as with every new concept in the U.S. health care arena, there are growing pains, fear and uncertainty.

    In order to establish a value-based contract, pharmaceutical manufacturers as well as purchasers must understand the complexity of these agreements and the legal implications associated with it. Manufacturers will need to ensure safe harbor protection under the Anti-Kickback Statute to enter qualified value based contracts. As there is a greater exchange of more data between stakeholders, manufacturers must mitigate HIPAA risks including reporting of adverse events and sharing of patient data. They must also understand the legal regulations necessary to take into account within value based contracts.

    Special concerns must be addressed in pharmaceutical value based agreements with non-traditional purchasers such as hospitals, hospital systems, integrated delivery networks (IDNs) and ACOs. These challenges include rebates and government programs, and incorporating provisions in regard to these agreements to compliantly address best price calculations.

    Sidley Austin
    William A. Sarraille

    via Ann Miller RN MHA

    Like

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: